Reflux Esophagitis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years and <=75 years, with no gender restriction. 2.Patients diagnosed with reflux esophagitis of Los Angeles (LA) Grade A to D by endoscopy. 3.Participants have been informed of all relevant requirements of the study, are willing to participate, and have provided written informed consent.
Exclusion criteria
Exclusion criteria: 1.Hypersensitivity to valagliflozin proglumetac or any of its excipients; 2.Current use of atazanavir, nelfinavir, or rilpivirine (to avoid drug-drug interactions); 3.Pregnant or lactating female; or female of childbearing potential with a positive blood/urine pregnancy test during the screening period; or female of childbearing potential unwilling to use effective contraceptive measures during the study; 4.Subjects judged by the investigator to have severe disorders of the central nervous system, respiratory system, urinary system, endocrine system, or hematological system, which may confound study results, compromise subject safety, or constitute other conditions inappropriate for trial participation. 5.Patients with severe hepatic and renal insufficiency, defined as: liver cirrhosis of Child-Pugh Class B/C, markedly abnormal liver function laboratory parameters (e.g., ALT/AST > 3 × upper limit of normal, INR > 1.5), or end-stage renal disease with an estimated glomerular filtration rate < 30 mL/min/1.73 m^2.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| At the end of the 8-week treatment period, the proportion of patients with endoscopically confirmed esophageal mucosal healing was compared between the two groups.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement of symptoms;Safety; | — |
Countries
China
Contacts
The First Affiliated Hospital of Wenzhou Medical University